The Drug Enforcement Administration (DEA) announced on Friday that it will be reinstating federal requirements for powerful drugs such as OxyContin and Adderall, which were waived when the COVID-19 pandemic began. This move is seen as a way to address the opioid crisis and ensure that patients are getting the right medications and that they are being used safely and effectively. The new requirements will go into effect in the coming months and the DEA will be working with healthcare providers to ensure compliance.
